Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications.

angiogenesis angiogenic cytokines extracellular vesicles multiple myeloma

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
08 May 2023
Historique:
received: 04 01 2023
revised: 20 04 2023
accepted: 27 04 2023
medline: 27 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

Extracellular vesicles (EVs) have emerged as important players in cell-to-cell communication within the bone marrow (BM) of multiple myeloma (MM) patients, where they mediate several tumor-associated processes. Here, we investigate the contribution of fibroblasts-derived EVs (FBEVs) in supporting BM angiogenesis. We demonstrate that FBEVs' cargo contains several angiogenic cytokines (i.e., VEGF, HGF, and ANG-1) that promote an early over-angiogenic effect independent from EVs uptake. Interestingly, co-culture of endothelial cells from MM patients (MMECs) with FBEVs for 1 or 6 h activates the VEGF/VEGFR2, HGF/HGFR, and ANG-1/Tie2 axis, as well as the mTORC2 and Wnt/β-catenin pathways, suggesting that the early over-angiogenic effect is a cytokine-mediated process. FBEVs internalization occurs after longer exposure of MMECs to FBEVs (24 h) and induces a late over-angiogenic effect by increasing MMECs migration, chemotaxis, metalloproteases release, and capillarogenesis. FBEVs uptake activates mTORC1, MAPK, SRC, and STAT pathways that promote the release of pro-angiogenic cytokines, further supporting the pro-angiogenic milieu. Overall, our results demonstrate that FBEVs foster MM angiogenesis through dual time-related uptake-independent and uptake-dependent mechanisms that activate different intracellular pathways and transcriptional programs, providing the rationale for designing novel anti-angiogenic strategies.

Identifiants

pubmed: 37239071
pii: biomedicines11051400
doi: 10.3390/biomedicines11051400
pmc: PMC10216205
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Italian Association for Cancer Research
ID : 25706
Organisme : Regione Puglia
ID : INNOLABS-POR FESR-FSE 2014-2020 (Telemielolab)
Organisme : Italian Ministry for Education, University and Research
ID : 20174TB8KW002

Références

Cancers (Basel). 2023 Mar 27;15(7):
pubmed: 37046651
Cell Commun Signal. 2022 Apr 7;20(1):49
pubmed: 35392964
J Clin Med. 2020 Jun 06;9(6):
pubmed: 32517267
Front Oncol. 2021 Feb 09;10:625199
pubmed: 33634031
Am J Pathol. 2021 Apr;191(4):748-758
pubmed: 33516787
Biomedicines. 2020 Nov 06;8(11):
pubmed: 33171974
Blood. 2014 Dec 11;124(25):3748-57
pubmed: 25320245
Leukemia. 2016 Mar;30(3):640-8
pubmed: 26487273
J Pathol. 2022 Apr;256(4):402-413
pubmed: 34919276
Oncotarget. 2016 Mar 22;7(12):14510-21
pubmed: 26919105
Thromb Haemost. 2004 Dec;92(6):1438-45
pubmed: 15583754
Dev Cell. 2019 Feb 25;48(4):573-589.e4
pubmed: 30745143
Front Cell Dev Biol. 2020 Jul 07;8:584
pubmed: 32775327
Front Cell Dev Biol. 2016 Sep 21;4:99
pubmed: 27709112
Chem Immunol Allergy. 2014;99:180-96
pubmed: 24217610
Transl Oncol. 2021 Dec;14(12):101231
pubmed: 34601397
PLoS One. 2020 Apr 10;15(4):e0231430
pubmed: 32275689
Oncogene. 2019 Jun;38(26):5227-5238
pubmed: 30890754
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Blood. 2003 Nov 1;102(9):3340-8
pubmed: 12855563
J Hematol Oncol. 2019 Jan 9;12(1):4
pubmed: 30626425
Front Oncol. 2021 Jun 21;11:689538
pubmed: 34235082
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4852-7
pubmed: 21368175
Cell Rep. 2021 May 18;35(7):109139
pubmed: 34010648
Oncotarget. 2018 Apr 17;9(29):20563-20577
pubmed: 29755672
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Front Immunol. 2016 Sep 22;7:378
pubmed: 27713747
Clin Cancer Res. 2014 Nov 15;20(22):5796-807
pubmed: 25212607
Proteomics. 2021 Jul;21(13-14):e2000119
pubmed: 33580572
Front Cell Dev Biol. 2022 Jul 08;10:919438
pubmed: 35874817
Lancet. 2021 Jan 30;397(10272):410-427
pubmed: 33516340
Oncotarget. 2014 Jul 30;5(14):5686-99
pubmed: 25015330
Angiogenesis. 2005;8(1):43-51
pubmed: 16132617
Sci Rep. 2018 Jun 12;8(1):8973
pubmed: 29895824
Nat Rev Mol Cell Biol. 2022 May;23(5):369-382
pubmed: 35260831
J Immunol. 2006 Jun 15;176(12):7385-93
pubmed: 16751383
J Clin Med. 2022 Nov 01;11(21):
pubmed: 36362718
Curr Cancer Drug Targets. 2008 Feb;8(1):19-26
pubmed: 18288940
J Pathol. 2016 Jun;239(2):162-73
pubmed: 26956697
Front Oncol. 2021 Aug 27;11:718502
pubmed: 34513695
Exp Ther Med. 2020 Mar;19(3):1997-2007
pubmed: 32104259
Blood Adv. 2017 May 16;1(13):812-823
pubmed: 29296725
Leukemia. 2014 Apr;28(4):904-16
pubmed: 23995611
J Exp Med. 1996 Mar 1;183(3):1161-72
pubmed: 8642258
J Extracell Vesicles. 2021 Sep;10(11):e12140
pubmed: 34520123
J Allergy Clin Immunol. 2010 Feb;125(2):477-82
pubmed: 20159258
Int J Mol Sci. 2018 Jul 12;19(7):
pubmed: 30002349

Auteurs

Aurelia Lamanuzzi (A)

Unit of Internal Medicine and Clinical Oncology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70124 Bari, Italy.

Ilaria Saltarella (I)

Unit of Internal Medicine and Clinical Oncology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70124 Bari, Italy.
Unit of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70121 Bari, Italy.

Antonia Reale (A)

Myeloma Research Group, Australian Centre for Blood Diseases, Central Clinical School, Monash University-Alfred Health, Melbourne, VIC 3004, Australia.

Assunta Melaccio (A)

Unit of Internal Medicine and Clinical Oncology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70124 Bari, Italy.

Antonio Giovanni Solimando (AG)

Unit of Internal Medicine and Clinical Oncology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70124 Bari, Italy.

Concetta Altamura (C)

Unit of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70121 Bari, Italy.

Grazia Tamma (G)

Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, 70121 Bari, Italy.

Clelia Tiziana Storlazzi (CT)

Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, 70121 Bari, Italy.

Doron Tolomeo (D)

Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, 70121 Bari, Italy.

Vanessa Desantis (V)

Unit of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70121 Bari, Italy.

Maria Addolorata Mariggiò (MA)

Unit of Clinical Pathology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70121 Bari, Italy.

Jean-François Desaphy (JF)

Unit of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70121 Bari, Italy.

Andrew Spencer (A)

Myeloma Research Group, Australian Centre for Blood Diseases, Central Clinical School, Monash University-Alfred Health, Melbourne, VIC 3004, Australia.
Malignant Haematology and Stem Cell Transplantation, Department of Haematology, Alfred Hospital, Melbourne, VIC 3004, Australia.
Department of Clinical Hematology, Monash University, Melbourne, VIC 3004, Australia.

Angelo Vacca (A)

Unit of Internal Medicine and Clinical Oncology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70124 Bari, Italy.

Benedetta Apollonio (B)

Unit of Internal Medicine and Clinical Oncology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70124 Bari, Italy.

Maria Antonia Frassanito (MA)

Unit of Clinical Pathology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70121 Bari, Italy.

Classifications MeSH